| Similar Articles |
|---|
 |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.   |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
June 2005
Nancy J. Kelley |
Building Centers of Excellence in Translational Medicine New approaches to drug development that will be more effective in translating research to patient delivery will require the design and construction of new facilities that foster new ways of working among larger, multidisciplinary, teams of scientists and medical professionals in biology, chemistry, physics, mathematics, engineering, computer science, and, of course, information technology. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
Pharmaceutical Executive
July 1, 2009 |
Swallowing the Innovator's Rx Capitalize on the new age in healthcare with "disruptive innovation." |
Pharmaceutical Executive
November 1, 2011
Elizabeth O. Coulton |
Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients. |
Pharmaceutical Executive
September 1, 2011
Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Bio-IT World
June 2006
Kevin Davies |
The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
February 23, 2005
John Reeves |
Predicting the Next Wal-Mart Studying the history of disruptive innovation can help us find tomorrow's winners. |
The Motley Fool
October 26, 2010
Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer." |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Pharmaceutical Executive
December 1, 2011
George Baeder |
China's Future in Bioscience Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse? |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
Bio-IT World
May 9, 2003
Mark D. Uehling |
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Bio-IT World
March 10, 2003
Dawn Stover |
E-Recruitment: Trial by Wire Online databases are helping patients find clinical trials -- but e-recruitment is no panacea for participant shortages. |
Chemistry World
September 2009 |
Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Pharmaceutical Executive
October 1, 2008
RS Kumar |
Evolving Clinical Trials Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in efficiency. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
From Locked Box to Data Sphere Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery. |
Wired
March 2006
Jennifer Kahn |
A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials. |
Bio-IT World
November 14, 2003
Jeff Augen |
Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Pharmaceutical Executive
March 1, 2013
Ken Getz |
Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
| Fast Company |
The World's Top 10 Most Innovative Companies In Health Care Medivation, Beijing Genomics Institute, and MediSafe make the list of companies. |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
Pharmaceutical Executive
May 1, 2012 |
Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards. |
Managed Care
May 2005
Martin Sipkoff |
Predictive Modeling & Genomics: Marriage of Promise and Risk Integration of predictive modeling and genomic tools means improved technology, enhanced databases, and appropriate legal guidance. |
Pharmaceutical Executive
September 1, 2013
Jill Wechsler |
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Chemistry World
July 2008
William Bains |
Beyond shareholder returns The author offers a new model for the pharmaceutical industry |
HBS Working Knowledge
July 25, 2011
Christensen & Eyring |
How Disruptive Innovation is Remaking the University Online learning is a disruptive technology that is making colleges and universities reconsider their higher education models. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Pharmaceutical Executive
September 1, 2012
Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
